HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dalila Sellami Selected Research

sonidegib

1/2017A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.
12/2016Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
11/2016Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.
7/2016The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
4/2016Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
6/2015Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dalila Sellami Research Topics

Disease

11Neoplasms (Cancer)
12/2023 - 04/2004
4Breast Neoplasms (Breast Cancer)
10/2023 - 01/2018
4Basal Cell Carcinoma (Rodent Ulcer)
01/2017 - 06/2015
3Hyperglycemia
01/2019 - 08/2018
2Fatigue
01/2018 - 09/2014
2Hepatocellular Carcinoma (Hepatoma)
05/2015 - 12/2013
1Brain Neoplasms (Brain Tumor)
12/2023
1Neoplasm Metastasis (Metastasis)
12/2023
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2023
1Disease Progression
10/2023
1Triple Negative Breast Neoplasms
10/2023
1Exanthema (Rash)
01/2019
1Leukopenia
08/2018
1Acute Kidney Injury (Acute Renal Failure)
08/2018
1Hypertension (High Blood Pressure)
01/2018
1Squamous Cell Carcinoma of Head and Neck
01/2018
1Pleural Effusion (Pleural Effusions)
01/2018
1Heart Failure
01/2018
1Cardiac Arrhythmias (Arrythmia)
12/2016
1Torsades de Pointes (Torsade de Pointes)
12/2016
1Tuberous Sclerosis (Bourneville's Disease)
05/2015
1Diarrhea
09/2014
1Stomatitis
09/2014
1Renal Cell Carcinoma (Grawitz Tumor)
09/2014
1Thrombocytopenia (Thrombopenia)
12/2013
1Tinea Capitis
04/2004

Drug/Important Bio-Agent (IBA)

6sonidegibIBA
01/2017 - 06/2015
4ErbB Receptors (EGF Receptor)IBA
12/2023 - 11/2018
4Hormones (Hormone)IBA
10/2023 - 01/2018
3Fulvestrant (Faslodex)FDA Link
01/2019 - 01/2018
3NVP-BKM120IBA
11/2018 - 01/2018
3EverolimusFDA Link
05/2015 - 12/2013
2patritumab deruxtecanIBA
12/2023 - 10/2023
2PlatinumIBA
12/2023 - 01/2018
2AlpelisibIBA
01/2019 - 08/2018
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
11/2018 - 01/2018
2Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
11/2018 - 08/2018
2Alanine Transaminase (SGPT)IBA
11/2018 - 01/2018
2Paclitaxel (Taxol)FDA LinkGeneric
08/2018 - 01/2018
1N 30IBA
12/2023
1Tyrosine Kinase InhibitorsIBA
12/2023
1Immunoconjugates (Immunoconjugate)IBA
10/2023
1Letrozole (Femara)FDA LinkGeneric
01/2019
1MTOR InhibitorsIBA
01/2018
1Biomarkers (Surrogate Marker)IBA
01/2018
1HhAntag691IBA
01/2017
1Smoothened ReceptorIBA
11/2016
1Mechanistic Target of Rapamycin Complex 1IBA
05/2015
1trans-sodium crocetinate (crocetin)IBA
05/2015
1Sunitinib (Sutent)FDA Link
09/2014
1Sorafenib (BAY 43-9006)FDA Link
12/2013

Therapy/Procedure

4Therapeutics
12/2023 - 12/2013
2Drug Therapy (Chemotherapy)
12/2023 - 01/2018
1Radiotherapy
01/2017
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
10/2005
1X-Ray Therapy
04/2004